| Aug 6 |
Personalis Q2 2024 Earnings Preview
|
| Aug 6 |
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
|
| Jul 31 |
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
|
| Jul 24 |
Personalis to Announce Second Quarter 2024 Financial Results
|
| Jul 19 |
Even after rising 48% this past week, Personalis (NASDAQ:PSNL) shareholders are still down 89% over the past three years
|
| Jul 15 |
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
|
| Jul 11 |
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
|
| Jun 18 |
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
|
| Jun 13 |
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
|
| Jun 4 |
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
|
